Free Trial
NASDAQ:IPSC

Century Therapeutics Q4 2023 Earnings Report

Century Therapeutics logo
$0.50 -0.03 (-5.38%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$0.52 +0.02 (+3.45%)
As of 04/25/2025 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Century Therapeutics EPS Results

Actual EPS
-$0.49
Consensus EPS
-$0.56
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

Century Therapeutics Revenue Results

Actual Revenue
$0.27 million
Expected Revenue
$1.69 million
Beat/Miss
Missed by -$1.42 million
YoY Revenue Growth
N/A

Century Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Thursday, March 14, 2024
Conference Call Time
5:00AM ET

Upcoming Earnings

Century Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Monday, May 12, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Century Therapeutics Earnings Headlines

Piper Sandler Remains a Buy on Century Therapeutics (IPSC)
Real Americans Don’t Wait on Wall Street’s Next Move
What's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.
See More Century Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Century Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Century Therapeutics and other key companies, straight to your email.

About Century Therapeutics

Century Therapeutics (NASDAQ:IPSC), a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

View Century Therapeutics Profile

More Earnings Resources from MarketBeat